The phosphatidylinositol 3-kinase inhibitor, PX-866, is a potent inhibitor of cancer cell motility and growth in three-dimensional cultures

Molecular Cancer Therapeutics

Volumn 6, Issue 9, 2007, Pages 2505-2514

  Howes, Amy L ^a   Chiang, Gary G ^a   Lang, Elizabeth S ^a   Ho, Caroline B ^a   Powis, Garth ^b   Vuori, Kristiina ^a   Abraham, Robert T ^a  

^a BURNHAM INSTITUTE   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOXORUBICIN; PHOSPHATASE; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PX 866; RAPAMYCIN; UNCLASSIFIED DRUG; WORTMANNIN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER; CANCER GROWTH; CANCER INHIBITION; CELL GROWTH; CELL MOTILITY; CELL TRANSFORMATION; COLON CANCER; CONTROLLED STUDY; CYTOSTASIS; DRUG POTENCY; ENZYME ACTIVITY; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VIVO STUDY; MALE; METASTASIS; METASTASIS INHIBITION; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN PHOSPHORYLATION; SIGNAL DETECTION; SPHEROID CELL; TUMOR XENOGRAFT;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANDROSTADIENES; CELL MOVEMENT; CELL PROLIFERATION; ENZYME INHIBITORS; GONANES; HUMANS; NEOPLASMS; PHOSPHORYLATION; SPHEROIDS, CELLULAR; TUMOR CELLS, CULTURED;

EID: 34748840281     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-06-0698     Document Type: Article

References (30)

1. Luo J, Manning BD, Cantley LC. Targeting the PI3K-Akt pathway in human cancer: rationale and promise. Cancer Cell 2003;4:257-62.
2. Bachman KE, Argani P, Samuels Y, et al. The PIK3CA gene is mutated with high frequency in human breast cancers. Cancer Biol Ther 2004;3:772-5.
3. Broderick DK, Di C, Parrett TJ, et al. Mutations of PIK3CA in anaplastic oligodendrogliomas, high-grade astrocytomas, and medulloblastomas. Cancer Res 2004;64:5048-50.
4. Campbell IG, Russell SE, Choong DY, et al. Mutation of the PIK3CA gene in ovarian and breast cancer. Cancer Res 2004;64:7678-81.
5. Samuels Y, Wang Z, Bardelli A, et al. High frequency of mutations of the PIK3CA gene in human cancers. Science 2004;304:554.
6. Cantley LC, Neel BG. New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway. Proc Natl Acad Sci U S A 1999;96:4240-5.
7. Wymann MP, Bulgarelli-Leva G, Zvelebil MJ, et al. Wortmannin inactivates phosphoinositide 3-kinase by covalent modification of Lys-802, a residue involved in the phosphate transfer reaction. Mol Cell Biol 1996;16:1722-33.
8. Brunn GJ, Williams J, Sabers C, Wiederrecht G, Lawrence JC, Jr., Abraham RT. Direct inhibition of the signaling functions of the mammalian target of rapamycin by the phosphoinositide 3-kinase inhibitors, wortmannin and LY294002. EMBO J 1996;15:5256-67.
9. Sarkaria JN, Tibbetts RS, Busby EC, Kennedy AP, Hill DE, Abraham RT. Inhibition of phosphoinositide 3-kinase related kinases by the radiosensitizing agent wortmannin. Cancer Res 1998;58:4375-82.
10. Ihle NT, Williams R, Chow S, et al. Molecular pharmacology and antitumor activity of PX-866, a novel inhibitor of phosphoinositide-3-kinase signaling. Mol Cancer Ther 2004;3:763-72.
11. Ihle NT, Paine-Murrieta G, Berggren MI, et al. The phosphatidylinositol- 3-kinase inhibitor PX-866 overcomes resistance to the epidermal growth factor receptor inhibitor gefitinib in A-549 human non-small cell lung cancer xenografts. Mol Cancer Ther 2005;4:1349-57.
12. Griffith LG, Swartz MA. Capturing complex 3D tissue physiology in vitro. Nat Rev Mol Cell Biol 2006;7:211-24.
13. Wipf P, Minion DJ, Halter RJ, et al. Synthesis and biological evaluation of synthetic viridins derived from C(20)-heteroalkylation of the steroidal PI-3-kinase inhibitor wortmannin. Org Biomol Chem 2004;2:1911-20.
14. Kelm JM, Timmins NE, Brown CJ, Fussenegger M, Nielsen LK. Method for generation of homogeneous multicellular tumor spheroids applicable to a wide variety of cell types. Biotechnol Bioeng 2003;83:173-80.
15. Balla T, Varnai P. Visualizing cellular phosphoinositide pools with GFP-fused protein-modules. Sci STKE 2002;2002:PL3.
16. Gottfried E, Kunz-Schughart LA, Andreesen R, Kreutz M. Brave little world: spheroids as an in vitro model to study tumor-immune-cell interactions. Cell Cycle 2006;5:691-5.
17. Merlot S, Firtel RA. Leading the way: Directional sensing through phosphatidylinositol 3-kinase and other signaling pathways. J Cell Sci 2003;116:3471-8.
18. Stephens L, Ellson C, Hawkins P. Roles of PI3Ks in leukocyte chemotaxis and phagocytosis. Curr Opin Cell Biol 2002;14:203-13.
19. Fan QW, Knight ZA, Goldenberg DD, et al. A dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in glioma. Cancer Cell 2006;9:341-9.
20. Knight ZA, Gonzalez B, Feldman ME, et al. A pharmacological map of the PI3-K family defines a role for p110α in insulin signaling. Cell 2006;125:733-47.
21. Schultz RM, Merriman RL, Andis SL, et al. In vitro and in vivo antitumor activity of the phosphatidylinositol-3-kinase inhibitor, wortmannin. Anticancer Res 1995;15:1135-9.
22. Holleran JL, Egorin MJ, Zuhowski EG, Parise RA, Musser SM, Pan SS. Use of high-performance liquid chromatography to characterize the rapid decomposition of wortmannin in tissue culture media. Anal Biochem 2003;323:19-25.
23. Sliva D, Rizzo MT, English D. Phosphatidylinositol 3-kinase and NF-κB regulate motility of invasive MDA-MB-231 human breast cancer cells by the secretion of urokinase-type plasminogen activator. J Biol Chem 2002;277:3150-7.
24. Haas-Kogan D, Shalev N, Wong M, Mills G, Yount G, Stokoe D. Protein kinase B (PKB/Akt) activity is elevated in glioblastoma cells due to mutation of the tumor suppressor PTEN/MMAC. Curr Biol 1998;8:1195-8.
25. Myers MP, Pass I, Batty IH, et al. The lipid phosphatase activity of PTEN is critical for its tumor suppressor function. Proc Natl Acad Sci U S A 1998;95:13513-8.
26. Whyte DB, Holbeck SL. Correlation of PIK3Ca mutations with gene expression and drug sensitivity in NCI-60 cell lines. Biochem Biophys Res Commun 2006;340:469-75.
27. Furnari FB, Huang HJ, Cavenee WK. The phosphoinositol phosphatase activity of PTEN mediates a serum-sensitive G1 growth arrest in glioma cells. Cancer Res 1998;58:5002-8.
28. Koul D, Shen R, Bergh S, et al. Inhibition of Akt survival pathway by a small-molecule inhibitor in human glioblastoma. Mol Cancer Ther 2006;5:637-44.
29. Shingu T, Yamada K, Hara N, et al. Growth inhibition of human malignant glioma cells induced by the PI3-K-specific inhibitor. J Neurosurg 2003;98:154-61.
30. Liu M, Howes A, Lesperance J, et al. Antitumor activity of rapamycin in a transgenic mouse model of ErbB2-dependent human breast cancer. Cancer Res 2005;65:5325-36.